Search the Newsreel

Earnings call transcript: Aarti Drugs posts strong Q1 2026 growth as stock slips

Drugs Made In America Acquisition II Corp. Revenue Breakdown – BOATS:DMIIU

This article provides a brief overview of Drugs Made In America Acquisition II Corp. (DMIIU) financial information available on TradingView. It indicates that the market is closed and there are no trades for the company. The page focuses on fundamental data, statements, statistics, dividends, …

Sturm, Ruger & Co. posts Q2 sales $158.1M, adjusted EPS $0.52; declares $0.21 dividend

Sturm, Ruger & Co. reported strong Q2 2026 results, with net sales of $158.1 million and adjusted diluted EPS of $0.52, exceeding previous year's performance. The company declared a quarterly dividend of $0.21 per share and attributed its success to improved manufacturing, a stronger …

AARTIDRUGS: Q1 FY27 saw 19% revenue and 30% EBITDA growth, with margin expansion and strong operational execution

Kilitch Drugs posts 4% PAT rise in FY26, seeks ₹2 cr exec pay

Sturm, Ruger & Company, Inc. (NYSE:RGR) Upgraded to "Strong-Buy" at Wall Street Zen

Wall Street Zen has upgraded Sturm, Ruger & Company (NYSE:RGR) to "strong-buy" from "buy", despite broader analyst sentiment remaining a "Hold" with a $46 average price target. The company recently reported strong quarterly earnings, beating EPS and revenue estimates, with revenue up 19.3% year …

Enterprise value to EBITDA forward of Sturm, Ruger & Company, Inc. – NYSE:RGR

This article presents financial data for Sturm, Ruger & Company, Inc. (NYSE:RGR), specifically focusing on its enterprise value to EBITDA forward. It details the stock's performance and financial metrics, indicating that the market is currently closed with no trades. The content also lists various …

Ruger posts $158M Q2 sales, adjusted EBITDA margin 10.5% and $0.21 dividend

Ruger reported strong Q2 results with net sales of $158 million, a 19% increase from Q2 2025, driven by core products and higher manufacturing output. The company expanded its adjusted EBITDA margin to 10.5% and declared a quarterly dividend of $0.21 per share. Ruger …

Strong Q2 for Sturm Ruger (NYSE: RGR) with 19% sales jump and $0.52 EPS

Sturm, Ruger & Company reported a strong Q2 2026 with net sales increasing 19% to $158 million and adjusted diluted EPS rising to $0.52. The company achieved its fifth consecutive quarter of sales growth, improved manufacturing performance, and formally established the Ruger Business System …

Sturm Ruger (RGR) Stock Drops As Profit Returns Face Demand Doubts

Sturm Ruger (RGR) saw its stock drop by almost 5% despite reporting a return to profitability in Q2 2026, with net sales of US$158 million and basic EPS of US$0.44. The market reaction indicates investor concern over future demand, policy risks, and execution challenges …

AARTIDRUGS: Q1 FY27 saw strong revenue growth and stable profitability, focused on pharmaceuticals

Aarti Drugs Q1 profit falls 7% despite 19% revenue growth; announces leadership transition

Sturm, Ruger & Company, Inc. Q2 Earnings Call Highlights

Sturm, Ruger & Company, Inc. reported strong Q2 results with net sales up 19% to $158 million and diluted earnings of $0.43 per share, driven by increased production, improved product mix, and higher selling prices. The company is actively rebuilding inventory ahead of the …

Beta Drugs Consolidated June 2026 Net Sales at Rs 125.55 crore, up 25.29% Y-o-Y

Beta Drugs Standalone June 2026 Net Sales at Rs 55.83 crore, down 15.83% Y-o-Y

Sturm, Ruger & Company, Inc. (NYSE:RGR) Announces Dividend Increase - $0.21 Per Share

Sturm, Ruger & Company, Inc. (NYSE:RGR) has announced a significant increase in its quarterly dividend to $0.21 per share, a 90.9% jump from its previous $0.11. The company also reported strong quarterly earnings, beating analyst estimates with EPS of $0.52 and revenue of $158.06 …

Press Release: Sturm, Ruger & Company, Inc. Reports Second Quarter 2026 Results

Sturm, Ruger & Company, Inc. announced its financial results for the second quarter of 2026. The report details the company's performance during this period, including key financial metrics and potentially insights into sales, earnings, and market conditions relevant to the firearms industry. This press …

Sturm Ruger (NYSE: RGR) swings back to profit as firearm demand rises

Sturm, Ruger & Company, Inc. reported a significant return to profitability in Q2 2026, with net sales increasing to $158.1 million and net income reaching $6.981 million, compared to a loss in the prior year. This improvement was driven by higher firearms demand, better …

Sturm, Ruger Bangs Out 19 Percent Growth in Q2

Sturm, Ruger & Company, Inc. reported a 19.3% increase in Q2 sales, reaching $158.1 million, with diluted earnings of $0.43 per share. The company's performance was driven by strong product demand, improved manufacturing, and the introduction of the Ruger Business System, despite incurring $1.2 …

Sturm, Ruger & Company Releases Q2 2026 Financial Results

Sturm, Ruger & Company significantly surpassed Wall Street's expectations for its second quarter of 2026, driven by strong demand in the firearms market. The company reported adjusted earnings per share of $0.52 and revenue of $158.1 million, exceeding consensus estimates by 23.8% and 23.0% …

Sturm Ruger Swings to Profit as Firearms Demand Drives Revenue Growth

Sturm Ruger (RGR) reported a swing to profit in the second quarter, reaching $6.98 million, or 43 cents per share, compared to a loss in the previous year. This turnaround was driven by increased demand for its firearms, improved product mix, and a 10% …

Beta Drugs Ltd. Revenue Breakdown – NSE:BETA

Sturm, Ruger & Company (RGR) Releases Q2 2026 Earnings: Revenue Growth but EPS Decline

Sturm, Ruger & Company (RGR) reported strong Q2 2026 revenue of $158.1 million, exceeding Wall Street estimates by a significant margin and representing a 19.3% increase year-over-year. Despite this top-line growth and improved gross profit, the company experienced a decline in operating profit and …

Sturm Ruger: Q2 Earnings Snapshot

Sturm Ruger (NYSE: RGR) returns to profit in Q2 2026 and declares dividend

Sturm, Ruger & Company, Inc. Revenue Breakdown – MUN:ST2

Sturm, Ruger & Company, Inc. (MUN:ST2) generated 464.92 million EUR in revenue last year, primarily from its Firearms segment, which contributed 462.72 million EUR. The United States was the largest geographical contributor, accounting for the entire 464.92 million EUR for the year. This represents …

Beta Drugs Q1FY27 net profit rises 41% to ₹165 Mn on strong sales

Team Ruger's Lauryl Akenhead Earns High Lady at 2026 Sheepdog Showdown

Team Ruger's Lauryl Akenhead won the High Lady title at the 2026 Sheepdog Showdown, a national PRS Pro Series point match held in the Catskill Mountains. Akenhead achieved a score of 151 using her Ruger American® Gen II rifle, highlighting the rifle's reliability and …

Drugs Made In America Acquisition Corp (DMAA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Drugs Made In America Acquisition Corp (DMAA). It notes that no dividends have been distributed over the past five years. The page also displays current stock information, including its price, market cap, …

Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAA), focusing on its P/E ratio, P/B ratio, and fair value. As of July 24th, DMAA's stock was trading at $10.709 with a market cap of $361.09 million and a TTM …

162,795 Shares in Drugs Made In America Acquisition Corp. $DMAA Purchased by Sona Asset Management US LLC

RGR|Sturm Ruger & Company Inc|Price:38.708|Chg%:+0.478

Sturm Ruger & Company Inc (RGR) has strong fundamentals and high growth potential, though its valuation is considered fairly valued within the Leisure Products industry. The company recently turned to a loss but offers a high and stable dividend. Analysts have rated it as …

Drugs Made In America Acquisition Corp (DMAA) Balance Sheet

This article provides the balance sheet for Drugs Made In America Acquisition Corp (DMAA), detailing its quarterly and annual financial health. It includes key financial metrics such as cash, assets, liabilities, and shareholders' equity, allowing for an analysis of the company's fundamentals and liquidity. …

Drugs Made In America Acquisition Corp (DMAA) Cash Flow

This article provides an in-depth look at the cash flow statement for Drugs Made In America Acquisition Corp (DMAA), detailing its operating, investing, and financing activities. It presents both annual and quarterly data, highlighting significant changes such as a notable increase in operating cash …

TradingKey

This article provides the income statement for Drugs Made In America Acquisition Corp (DMAA), including quarterly and annual financial data. It details key metrics such as operating expenses, operating profit, net non-operating interest income, income before and after tax, net income, and earnings per …

Drugs Made In America Acquisition Corp

This article provides a company overview for Drugs Made In America Acquisition Corp (DMAA), including its stock performance and market capitalization. It notes that relevant revenue breakdown data by business segment and region have not yet been disclosed by the company. The page also …